This invention relates to macrocyclic compounds of formula (I) or (II) shown in the specification. These compounds can be used to treat hepatitis C virus infection.
这项发明涉及规范中显示的式(I)或(II)的大环化合物。这些化合物可用于治疗丙型肝炎病毒感染。
Oxygen Effect in the Iodo Lactonization of Unsaturated Carboxylic Acids Leading to 7- to 12-Membered Ring Lactones
作者:Bruno Simonot、Gerard Rousseau
DOI:10.1021/jo00099a019
日期:1994.10
The reaction of omega-alkenoic acids with bis(sym-collidine)iodine(I) hexafluorophosphate led to (iodomethyl) epsilon-caprolactones in good yields (49-75%) and medium ring iodo lactones in low yields (4-5%). The latter compounds have been obtained after introduction of an oxygen atom in the carbon chain. The position of the oxygen appeared important. This oxygen effect was explained by the stabilization of the intermediate iodonium ion by the oxygen atom.
Preparation of seven-membered and medium-ring lactones by iodo lactonization
作者:Bruno Simonot、Gerard Rousseau
DOI:10.1021/jo00053a002
日期:1993.1
Iodo lactonization of 6-heptenoic acid using bis(sym-collidine)iodine(I) hexafluorophosphate in methylene chloride led in high yield to 6-(iodomethyl)-hexanolide while with longer omega-ethylenic carboxylic acids the corresponding lactones were obtained in low yields; however, the presence of an oxygen atom in the carbon chain allowed the formation of medium-ring iodo lactones.
[EN] HCV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉASE DU VHC
申请人:TAIGEN BIOTECHNOLOGY CO LTD
公开号:WO2009139792A1
公开(公告)日:2009-11-19
This invention relates to macrocyclic compounds of formula (I) or (II) shown in the specification. These compounds can be used to treat hepatitis C virus infection.